Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer

P P Provenzano, S R Hingorani, P P Provenzano, S R Hingorani

Abstract

Pancreatic ductal adenocarcinomas (PDAs) are notoriously aggressive and resistant to treatment. They distinguish themselves further by their robust fibroinflammatory, or desmoplastic, stromal reaction and degree of hypovascularity. Recent findings have revealed multiple mechanisms of stromal complicity in disease pathogenesis and resistance. In this review, we focus on altered physicomechanics as one mechanism of what we term as 'stromal resistance' in PDA. Extremely high interstitial fluid pressures and a dense extracellular matrix combine to limit the delivery and distribution of therapeutic agents. We discuss the genesis and consequences of altered fluid dynamics in PDA and strategies to restore them.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The desmoplastic stroma in PDA. Both mouse (top) and human (bottom) PDA display robust deposition of ECM and activated pancreatic stellate cells. Masson’s trichrome reveals robust collagen content in PDA (blue) while a more complex Movat’s pentachrome staining highlights the presence of GAGs and mucins (blue) co-localised with collagen (turquoise/green). Histochemistry with hyaluronic acid binding protein (HABP) confirms the abundance of HA in PDA and immunohistochemistry for α-SMA identifies activated PSC, or myofibroblasts. Scale bars=50 μm.
Figure 2
Figure 2
Fluid and solid mechanics in distinct physiological states. (AC) Masson’s trichrome staining of normal pancreas, engrafted pancreas cancer cells, and autochthonous PDA. (A) Normal pancreata are composed largely of three epithelial compartments, namely ductal (d), acinar (ac), and islet cells (is), as well as ample functional vasculature and a scarce ECM. In tumours engrafted from purified carcinoma cells (B), the ECM is modest and numerous patent vessels are present. In contrast, autochthonous PDA (C) is dominated by a robust desmoplasia and a largely collapsed vasculature resulting in extremely limited perfusion. (DF) Schema for distinct states (for illustrative purposes only and not drawn to scale). (D) In normal tissue, the interstitial fluid pressure is low and dependent upon the vascular pressure and the oncotic gradient. (E) Tumour implants of isolated cancer cells or lines possess a moderate IFP that is also related to vascular pressure. (F) In autochthonous PDA, the IFP is very high and the vasculature already collapsed. While the exact mechanisms of the elevated IFP remain to be elucidated, our results allow us to formulate a number of testable hypotheses for the genesis and maintenance of these pressures and mechanics. After vascular collapse, free and HA-bound fluid is trapped in the interstitial space (initially at pressures that result from communication with the vascular space before collapse, e.g., ∼20 to 50 mm Hg plus additional swelling pressures transmitted though the fluid during and shortly after collapse). Following vascular collapse, we further hypothesise that the pressure in this now compartmentalised fluid continues to increase, contributed to by a combination of events in the solid components of the tumour. First, solid stress continues to increase and acts on adjacent fluid through ongoing ECM production, tumour cell and fibroblast proliferation, and immune cell infiltration; as these components increase the density of the tumour, fluid pressure will correspondingly rise. Second, we propose that cells, activated by tumour-expanding pressures, resist this deformation by increasing cellular contractile force to actively compact the tumour, further elevating fluid pressure. As a consequence of these events, fluid pressure in PDA is extremely high. We suggest that digestion of HA by treatment with PEGPH20 liberates bound water and also relaxes the hydrogel being actively counterposed by mechanical forces. As pressures begin to drop, expanding vessels permit mobilisation of excess fluid into the circulation. The rush of free fluid and relaxation of physical constraints may also now permit some direct leaking of fluid out of the tumour. For (D–F), ductal epithelial/PDA cells are shown in aqua, stellate cells in brown, macrophages in green, and T cells in orange. Collagen is illustrated in green and HA in yellow. Arrows indicate fluid pressures and small blue circles indicate water molecules. Scale bars, 25 μm for (A–C).

References

    1. Aguirre AJ, Bardeesy N, Sinha M, Lopez L, Tuveson DA, Horner J, Redston MS, DePinho RA (2003) Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 17(24): 3112–3126
    1. Allison DC, Piantadosi S, Hruban RH, Dooley WC, Fishman EK, Yeo CJ, Lillemoe KD, Pitt HA, Lin P, Cameron JL (1998) DNA content and other factors associated with ten-year survival after resection of pancreatic carcinoma. J Surg Oncol 67(3): 151–159
    1. Anas P, Neely WA, Hardy JD (1968) Interstitial fluid pressure changes in endotoxin shock. Surgery 63(6): 938–941
    1. Aukland K, Reed RK (1993) Interstitial-lymphatic mechanisms in the control of extracellular fluid volume. Physiol Rev 73(1): 1–78
    1. Balazs EA, Denlinger JL (1989) Clinical uses of hyaluronan. Ciba Found Symp 143: 265–275, discussion 275–280, 281–285
    1. Baxter LT, Jain RK (1989) Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection. Microvasc Res 37(1): 77–104
    1. Boucher Y, Jain RK (1992) Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. Cancer Res 52(18): 5110–5114
    1. Brekken C, Hjelstuen MH, Bruland OS, de Lange Davies C (2000) Hyaluronidase-induced periodic modulation of the interstitial fluid pressure increases selective antibody uptake in human osteosarcoma xenografts. Anticancer Res 20(5B): 3513–3519
    1. Bruera E, Neumann CM, Pituskin E, Calder K, Hanson J (1999) A randomized controlled trial of local injections of hyaluronidase versus placebo in cancer patients receiving subcutaneous hydration. Ann Oncol 10(10): 1255–1258
    1. Buchler P, Reber HA, Buchler M, Shrinkante S, Buchler MW, Friess H, Semenza GL, Hines OJ (2003) Hypoxia-inducible factor 1 regulates vascular endothelial growth factor expression in human pancreatic cancer. Pancreas 26(1): 56–64
    1. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15(6): 2403–2413
    1. Chain E, Duthie ES (1939) A mucolytic enzyme in testis extracts. Nature 144: 977–978
    1. Clark CE, Hingorani SR, Mick R, Combs C, Tuveson DA, Vonderheide RH (2007) Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res 67(19): 9518–9527
    1. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, Bennouna J, Bachet JB, Khemissa-Akouz F, Pere-Verge D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M Groupe Tumeurs Digestives of UnicancerPRODIGE Intergroup (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19): 1817–1825
    1. De Smedt SC, Lauwers A, Demeester J, Engelborghs Y, De Mey G, Du M (1994) Structural information on hyaluronic acid solutions as studied by probe diffusion experiments. Macromolecules 27(1): 141–146
    1. Dvorak HF, Nagy JA, Dvorak JT, Dvorak AM (1988) Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 133(1): 95–109
    1. Fadnes HO, Reed RK, Aukland K (1977) Interstitial fluid pressure in rats measured with a modified wick technique. Microvasc Res 14(1): 27–36
    1. Floyer MA (1966) The mechanism underlying the response of the hypertensive subject to a saline load. Expansion Sci Franc 1: 440–448
    1. Fukumura D, Jain RK (2007) Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J Cell Biochem 101(4): 937–949
    1. Guyton AC, Granger HJ, Taylor AE (1971) Interstitial fluid pressure. Physiol Rev 51(3): 527–563
    1. Heldin CH, Rubin K, Pietras K, Ostman A (2004) High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer 4(10): 806–813
    1. Helmlinger G, Netti PA, Lichtenbeld HC, Melder RJ, Jain RK (1997) Solid stress inhibits the growth of multicellular tumor spheroids. Nat Biotechnol 15(8): 778–783
    1. Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC, Grindey GB (1990) Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine). Cancer Res 50(14): 4417–4422
    1. Hidalgo M (2010) Pancreatic cancer. N Engl J Med 362(17): 1605–1617
    1. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, Ross S, Conrads TP, Veenstra TD, Hitt BA, Kawaguchi Y, Johann D, Liotta LA, Crawford HC, Putt ME, Jacks T, Wright CV, Hruban RH, Lowy AM, Tuveson DA (2003) Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4(6): 437–450
    1. Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, Rustgi AK, Chang S, Tuveson DA (2005) Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7(5): 469–483
    1. Hruban RH (2007) Tumors of the pancreas. In Atlas of Tumor Pathology, Hruban RH, Pitman MB, Klimstra DS, (eds) Washington, DC: Armed Forces Institute of Pathology
    1. Hruban RH, Goggins M, Parsons J, Kern SE (2000) Progression model for pancreatic cancer. Clin Cancer Res 6(8): 2969–2972
    1. Iacobuzio-Donahue CA (2012) Genetic evolution of pancreatic cancer: lessons learnt from the pancreatic cancer genome sequencing project. Gut 61(7): 1085–1094
    1. Izeradjene K, Combs C, Best M, Gopinathan A, Wagner A, Grady WM, Deng CX, Hruban RH, Adsay NV, Tuveson DA, Hingorani SR (2007) Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell 11(3): 229–243
    1. Jacobetz MA, Chan DS, Neesse A, Bapiro TE, Cook N, Frese KK, Feig C, Nakagawa T, Caldwell ME, Zecchini HI, Lolkema MP, Jiang P, Kultti A, Thompson CB, Maneval DC, Jodrell DI, Frost GI, Shepard HM, Skepper JN, Tuveson DA (2013) Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 62(1): 112–120
    1. Jain RK (1990) Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev 9(3): 253–266
    1. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307(5706): 58–62
    1. Katchalsky A (1954) Polyelectrolyte gels. Prog Biophys 4: 1–59
    1. Kindler HL, Ioka T, Richel DJ, Bennouna J, Letourneau R, Okusaka T, Funakoshi A, Furuse J, Park YS, Ohkawa S, Springett GM, Wasan HS, Trask PC, Bycott P, Ricart AD, Kim S, Van Cutsem E (2011) Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol 12(3): 256–262
    1. Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O'Reilly E, Wozniak TF, Picus J, Bhargava P, Mayer RJ, Schilsky RL, Goldberg RM (2010) Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 28(22): 3617–3622
    1. Koong AC, Mehta VK, Le QT, Fisher GA, Terris DJ, Brown JM, Bastidas AJ, Vierra M (2000) Pancreatic tumors show high levels of hypoxia. Int J Radiat Oncol Biol Phys 48(4): 919–922
    1. Less JR, Posner MC, Boucher Y, Borochovitz D, Wolmark N, Jain RK (1992) Interstitial hypertension in human breast and colorectal tumors. Cancer Res 52(22): 6371–6374
    1. Mahadevan D, Von Hoff DD (2007) Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther 6(4): 1186–1197
    1. Maitra A, Hruban RH (2008) Pancreatic cancer. Annu Rev Pathol 3: 157–188
    1. Meyer MF, Kreil G, Aschauer H (1997) The soluble hyaluronidase from bull testes is a fragment of the membrane-bound PH-20 enzyme. FEBS Lett 413(2): 385–388
    1. Milosevic MF, Fyles AW, Wong R, Pintilie M, Kavanagh MC, Levin W, Manchul LA, Keane TJ, Hill RP (1998) Interstitial fluid pressure in cervical carcinoma: within tumor heterogeneity, and relation to oxygen tension. Cancer 82(12): 2418–2426
    1. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25(15): 1960–1966
    1. Netti PA, Baxter LT, Boucher Y, Skalak R, Jain RK (1995) Time-dependent behavior of interstitial fluid pressure in solid tumors: implications for drug delivery. Cancer Res 55(22): 5451–5458
    1. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein WO, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B, Riess H (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297(3): 267–277
    1. Ogston AG (1966) On water binding. Fed Proc 25(3): 986–989
    1. Ogston AG, Michel CC (1978) General descriptions of passive transport of neutral solute and solvent through membranes. Prog Biophys Mol Biol 34(3): 197–217
    1. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, Frese KK, Denicola G, Feig C, Combs C, Winter SP, Ireland-Zecchini H, Reichelt S, Howat WJ, Chang A, Dhara M, Wang L, Ruckert F, Grutzmann R, Pilarsky C, Izeradjene K, Hingorani SR, Huang P, Davies SE, Plunkett W, Egorin M, Hruban RH, Whitebread N, McGovern K, Adams J, Iacobuzio-Donahue C, Griffiths J, Tuveson DA (2009) Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324(5933): 1457–1461
    1. Olson P, Chu GC, Perry SR, Nolan-Stevaux O, Hanahan D (2011) Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma. Proc Natl Acad Sci USA 108(49): E1275–E1284
    1. Ozerdem U (2009) Measuring interstitial fluid pressure with fiberoptic pressure transducers. Microvasc Res 77(2): 226–229
    1. Ozerdem U, Hargens AR (2005) A simple method for measuring interstitial fluid pressure in cancer tissues. Microvasc Res 70(1–2): 116–120
    1. Padera TP, Stoll BR, Tooredman JB, Capen D, di Tomaso E, Jain RK (2004) Pathology: cancer cells compress intratumour vessels. Nature 427(6976): 695.
    1. Park MS, Klotz E, Kim MJ, Song SY, Park SW, Cha SW, Lim JS, Seong J, Chung JB, Kim KW (2009) Perfusion CT: noninvasive surrogate marker for stratification of pancreatic cancer response to concurrent chemo- and radiation therapy. Radiology 250(1): 110–117
    1. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR (2012) Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21(3): 418–429
    1. Ramanujan S, Pluen A, McKee TD, Brown EB, Boucher Y, Jain RK (2002) Diffusion and convection in collagen gels: implications for transport in the tumor interstitium. Biophys J 83(3): 1650–1660
    1. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Horsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. New Engl J Med 364(6): 501–513
    1. Roberts E, Borges PR (1955) Patterns of free amino acids in growing and regressing tumors. Cancer Res 15(10): 697–699
    1. Roberts WG, Palade GE (1997) Neovasculature induced by vascular endothelial growth factor is fenestrated. Cancer Res 57(4): 765–772
    1. Scholander PF, Hargens AR, Miller SL (1968) Negative pressure in the interstitial fluid of animals. Fluid tensions are spectacular in plants; in animals they are elusively small, but just as vital. Science 161(3839): 321–328
    1. Sevick EM, Jain RK (1989) Geometric resistance to blood flow in solid tumors perfused ex vivo: effects of tumor size and perfusion pressure. Cancer Res 49(13): 3506–3512
    1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA: A Cancer Journal For Clinicians 62(1): 10–29
    1. Starling EH (1896) On the absorption of fluids from the connective tissue spaces. J Physiol 19(4): 312–326
    1. Stylianopoulos T, Martin JD, Chauhan VP, Jain SR, Diop-Frimpong B, Bardeesy N, Smith BL, Ferrone CR, Hornicek FJ, Boucher Y, Munn LL, Jain RK (2012) Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. Proc Natl Acad Sci US Am 109(38): 15101–15108
    1. Tanford C (1961) Physical Chemistry of Macromolecules. Wiley: New York
    1. Thompson CB, Shepard HM, O'Connor PM, Kadhim S, Jiang P, Osgood RJ, Bookbinder LH, Li X, Sugarman BJ, Connor RJ, Nadjsombati S, Frost GI (2010) Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models. Mol Cancer Therap 9(11): 3052–3064
    1. Toole BP (2004) Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 4(7): 528–539
    1. Toole BP, Slomiany MG (2008) Hyaluronan: a constitutive regulator of chemoresistance and malignancy in cancer cells. Semin Cancer Biol 18(4): 244–250
    1. Tredan O, Galmarini CM, Patel K, Tannock IF (2007) Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 99(19): 1441–1454
    1. Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias JL, Zhang H, Soon-Shiong P, Shi T, Rajeshkumar NV, Maitra A, Hidalgo M (2011) Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 29(34): 4548–4554
    1. Vonlaufen A, Joshi S, Qu C, Phillips PA, Xu Z, Parker NR, Toi CS, Pirola RC, Wilson JS, Goldstein D, Apte MV (2008) Pancreatic stellate cells: partners in crime with pancreatic cancer cells. Cancer Res 68(7): 2085–2093
    1. Warburg O (1956) On the origin of cancer cells. Science 123(3191): 309–314
    1. Wiederhielm C (1968) Microvascular, lymphatic, and interstitial pressures in the bat wing. Proc Intern Union Physiol Sci 7: 468
    1. Yang S, Wang X, Contino G, Liesa M, Sahin E, Ying H, Bause A, Li Y, Stommel JM, Dell'antonio G, Mautner J, Tonon G, Haigis M, Shirihai OS, Doglioni C, Bardeesy N, Kimmelman AC (2011) Pancreatic cancers require autophagy for tumour growth. Genes Dev 25(7): 717–729
    1. Zimmer HG, Millar HD (1998) Technology and application of ultraminiature catheter pressure transducers. Can J Cardiol 14(10): 1259–1266

Source: PubMed

3
구독하다